This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Risk of Bleeding With Dabigatran in Atrial Fibrillation

Thursday, November 6, 2014

Submitted by


Source Name: JAMA Internal Medicine


Hernandez I, Baik SH, Piñera A, Zhang Y.

This is a new “real-world” study comparing bleeding risk in Medicare patients treated with dabigatran (n=1302) and warfarin (n=8102) for newly diagnosed atrial fibrillation. The use of dabigatran was associated with a significantly higher risk of any, major, and gastrointestinal bleeding when compared with warfarin. On the contrary, intracraneal bleeding was significantly less common among patients on dabigatran.

Add comment

Log in or register to post comments